| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐114 mm Hg after 2 and 4 weeks' placebo run‐in; 8‐week double‐blind treatment |
| Participants |
Candesartan 8 mg: n=82(47 males,35 females); mean age=60(11) years; baseline sitting SBP=169(14) mm Hg, DBP=102(5) mm Hg;
Candesartan 16 mg: n=84(56 males,28 females); mean age=59(10) years; baseline sitting SBP=168(15) mm Hg, DBP=103(5) mm Hg;
Losartan 50 mg: n=83(47 males,36 females); mean age=59(9) years; baseline sitting SBP=168(16) mm Hg, DBP=104(5) mm Hg;
Placebo: n=85(38 males,47 females); mean age=60(10) years; baseline sitting SBP=170(14) mm Hg, DBP=103(5) mm Hg |
| Interventions |
Candesartan 8 mg once daily;
Candesartan 16 mg once daily;
Losartan 50 mg once daily;
Placebo;
take in the morning |
| Outcomes |
Trough sitting SBP/DBP using fully automatic device (Omron HEM‐705CP);
Peak sitting SBP/DBP using fully automatic device (Omron HEM‐705CP);
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SD reported, baseline SD reported; imputed endpoint SD for SD of change; BP data from Table II, p. 55; Jadad score=4; funding source= Astra Hassle AB, Sweden |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
